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Highlights 
 Ultra has detected Mycobacterium tuberculosis in the urine of a patient with renal TB 
 Use of Xpert or Ultra on urine is not currently recommended due to lack of evidence 
 Urine Ultra may be useful in the diagnosis of extra-pulmonary TB in persons with HIV 
 Further study is required to characterise the diagnostic accuracy of urine Ultra 
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Abstract 
In January 2017, the World Health Organisation recommended the Xpert® MTB/RIF Ultra 
assay (Ultra) for tuberculosis (TB) diagnosis. Ultra offers improved analytical sensitivity when 
compared with the initial Xpert® MTB/RIF (Xpert) assay for the detection of Mycobacterium 
tuberculosis. Ultra is therefore likely to be of particular benefit for detecting paucibacillary TB.  
We present a case from Uganda demonstrating Ultra positivity in urine from an HIV-infected 
patient presenting with altered mental status and urinary incontinence, and no other signs of 
active pulmonary or extrapulmonary TB. This represents the first published instance of a 
diagnosis of extrapulmonary TB made on the basis of a positive urine Ultra assay. 
The use of Ultra on urine may be a useful addition to the diagnostic armamentarium for 
disseminated TB in persons with HIV co-infection. The diagnostic accuracy of urine Ultra 
should be characterised further via prospective studies. 
 
Key words: Mycobacterium tuberculosis; Urine; Xpert MTB/RIF Ultra; Renal tuberculosis 
 
Introduction 
The use of the Xpert® MTB/RIF assay (Xpert) nucleic acid amplification test was first 
recommended for the diagnosis of tuberculosis (TB) by the World Health Organisation 
(WHO) in 2010.1 This fully-automated polymerase chain reaction (PCR) test represented a 
significant step forward in TB diagnostics. Xpert offered both increased accuracy and speed 
of diagnosis over the traditional microscopy and culture, as well as the ability to detect 
rifampicin resistance. In January 2017, Cepheid introduced the next generation of Xpert® 
named Xpert® MTB/RIF Ultra (Ultra). This offered improved sensitivity over Xpert in the 
diagnosis of pulmonary TB, most marked in people with HIV co-infection (5.4% higher 
overall (95% CI +3.3, +8.0%), 13% higher in HIV-infected (95% CI, +6.4, +21%)), although 
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with lower specificity (2.7% lower than Xpert (95% CI -1.7, -3.9)).2 Sensitivity in TB 
meningitis was two-fold improved over Xpert.3 
Although introduced for use on sputum samples, and since endorsed by the WHO for 
use on cerebrospinal fluid (CSF),4 the use of Xpert or Ultra with more easily accessible 
samples (e.g. stool, urine, blood) is not currently recommended due to a lack of evidence.1 
Currently, the WHO recommends the use of urine as a diagnostic specimen in TB only with 
the TB lipoarabinomannan (TB-LAM) antigen lateral flow assay (Alere).5 
Renal TB is a common form of extra-pulmonary TB in HIV-infected persons and 
originates primarily from the haematogenous spread of tuberculous bacilli from a respiratory 
focus. Post-mortem evidence of renal TB microabscesses exists in 50-69% of disseminated 
TB infections among HIV-infected persons.6 Urine microscopy and mycobacterial culture 
remains the gold standard for diagnosis; however, sensitivity is low (with a culture yield 
reported as around 46% in HIV-negative persons) and results take up to six weeks.7 
Previous work has shown an increased diagnostic yield in HIV-infected persons;8 however, 
evidence from the antiretroviral therapy era is limited. A recent study which used Xpert on 
urine samples demonstrated a 94.6% sensitivity for renal TB when compared to urine 
mycobacterial culture.7 
Case Presentation 
A 56-year-old HIV-infected female presented to Kiruddu General Hospital, Kampala, 
Uganda accompanied by her 17-year-old daughter. Her daughter reported a three-week 
history of gradual onset confusion, neck pain, and generalised body weakness. In addition, 
she had urinary incontinence for several months. She reported no systemic symptoms of TB.  
 She had been on antiretroviral therapy (ART) and prophylactic cotrimoxazole for 12 
years. She attended her HIV clinic every 1-2 months, with good compliance. She had 
undergone two previous changes to her antiretroviral regimen: the first three years prior due 
to virologic failure, from zidovudine, lamivudine and nevirapine to second line tenofovir, 
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lamivudine and atazanavir/ritonavir. Her second change three months prior to admission was 
after having discontinued ART for two weeks when developing urinary incontinence. 
Thereafter, her tenofovir was switched to abacavir. Her most recent HIV viral load was 251 
copies/ml with a CD4 of 384 cells/l (9 months prior to admission). Repeat plasma HIV viral 
load during the current admission was 1840 copies/ml, and CSF viral load was 32,000 
copies/ml. 
She was treated for cryptococcal meningitis 12 years prior and had been taking 
fluconazole secondary prophylaxis since. In addition, she completed treatment for pulmonary 
TB (confirmed by sputum Xpert) three years prior. She was known to have type II diabetes 
mellitus, and took regular metformin and glibenclamide. 
On admission, she was afebrile with other vital signs within normal range, and a 
random blood glucose of 7.4mM (133 mg/dL). On examination, she had a Glasgow coma 
scale score of 14 (of 15 possible) due to confusion but no focal neurological signs.  She had 
no evidence of wasting and no palpable lymphadenopathy. She had mild generalised 
abdominal tenderness with no palpable masses or organomegaly, and no abnormalities on 
thoracic examination.  
 
Management and Outcome 
Diagnostic work-up was commenced for altered mental status and possible 
meningitis; a lumbar puncture was recommended but initially declined by proxy. A serum 
cryptococcal antigen lateral flow assay (CrAg) was negative so she received three doses of 
intravenous (IV) ceftriaxone for potential bacterial aetiology, as well as maintenance IV 
normal saline. A urinary catheter was inserted. 
By the fifth day of admission, no improvement had occurred. A lumbar puncture was 
performed with proxy consent which demonstrated a CSF lymphocytosis of 220 cells/L, but 
was otherwise unremarkable (protein 48mg/dL; glucose error; CrAg negative). CSF 
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microscopy was negative for organisms (including acid-fast bacilli), negative on bacterial 
culture, and both CSF Xpert and Ultra were negative. CSF mycobacterial growth indicator 
tube culture was negative after six weeks. 
On the sixth day of admission, a catheterised urine sample was negative on TB-LAM 
assay; however, the centrifuged urine was positive for M. tuberculosis by Ultra (‘very low’; 
Supplemental Figure 1). Blood and centrifuged urine were both sent for mycobacterial 
culture with results negative after six weeks. 
On the eighth day of admission, in the absence of any other causative organism or 
pathology being identified as a cause of her altered mental status and urinary symptoms, the 
decision was made to commence the patient on anti-tuberculous therapy for treatment of 
renal TB. A rifabutin-based regimen was started (rifampicin being contraindicated due to 
pharmacokinetic interaction with atazanavir), and she was discharged on day 14.  She was 
reviewed in clinic on day 20 (at 13 days of TB therapy), and via telephone consultation after 
6 weeks, at which point she was noted have improved orientation and mobility and her neck 
pain had resolved.  
 
Discussion 
We report the first case in which Ultra performed on the urine has been instrumental 
in identifying disseminated TB in a HIV-infected woman, presenting with non-specific 
symptoms in a high TB prevalence area. It remains unclear in this instance whether this 
represents relapse of her prior TB infection or reinfection. We feel it is probable that her 
disseminated TB infection included the central nervous system in light of her confusion, neck 
pain and CSF lymphocyte pleocytosis. Against the uniform case definition for TB meningitis 
she scored 12 points categorising her as a ‘probable’ TBM case9. The negative CSF Xpert 
and Ultra results demonstrate the imperfect negative predictive value of the assays for CNS 
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TB which can be compounded by collection of small volumes of CSF or infection of the brain 
tissue or spinal cord without release of TB DNA into the CSF. 
The utility of Xpert on urine has already been described,10,11 with meta-analysis 
reporting a summary sensitivity of 0.87 (0.66–0.96) and specificity of 0.91 (0.84–0.95).10 A 
more recent study of concentrated urine in renal TB patients reported sensitivity of 0.95 
(0.87–1.00) and specificity of 0.87 (0.81–0.93) when compared to conventional culture.8  
Ultra has an 8-fold lower analytical limit of detection than Xpert (~15 CFU/ml versus 
100-120 CFU/ml respectively),13 so Ultra is potentially more sensitive in paucibacillary TB. 
So far, Ultra’s improved sensitivity has been demonstrated in the diagnosis of HIV-
associated TB meningitis and HIV-associated pulmonary TB.2,3 
Furthermore, specificity of both Xpert and Ultra is increased via a pre-amplification 
wash step, which ensures that DNA is only detected when associated with tuberculous bacilli 
(and not trans-renal free DNA or environmental contamination). A positive result in urine is 
therefore specific for renal TB, likely secondary to disseminated disease. False-positive 
results are recognised in the sputum of patients previously treated for pulmonary TB, due to 
persistent viable or non-viable bacilli of Mycobacterium tuberculosis. False positive results 
on sputum from prior TB infection are often in the ‘trace’ semi-quantitative category.2 The 
fact this lady’s result was in the ‘very low’ category adds weight to this being a true positive 
result, though we cannot exclude this result representing prior renal TB or disseminated 
tuberculosis. 
Urine TB-LAM is currently WHO-recommended for the diagnosis of HIV-associated 
TB disease in persons with CD4 <200 cells/L. Those with advanced immunosuppression 
have higher risk of disease dissemination with consequent renal involvement releasing LAM 
glycolipid into the urine. A prior study reported good correlation between urine Xpert and TB-
LAM, both markers of renal TB,6,14 although more recent data suggest only a small 
incremental diagnostic yield of urine Xpert over TB-LAM.15 Whether Ultra will have a greater 
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incremental value deserves exploring. However, in the case reported above, urine TB-LAM 
was negative, and without a positive Ultra result, the extrapulmonary TB may have been 
missed. This discordancy in Ultra and TB-LAM results may represent the greater sensitivity 
of Ultra. Further prospective studies are required to assess whether Ultra is beneficial in 
conjunction with other TB diagnostics (such as urine TB-LAM) to provide a novel method for 
diagnosing renal TB and HIV-associated disseminated TB. 
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